James A. Beer, a director at Docusign, INC. (NASDAQ: DOCU), executed a sale of 450 shares of the company’s common stock on March 3, 2026. The shares were sold at $45.02 apiece, producing a transaction value of $20,259. Following that sale, Beer retained direct ownership of 14,757 shares of Docusign stock.
Recent individual transactions preceding the March 3 sale include activity on February 28, 2026. On that date Beer exercised options to acquire 729 shares of Docusign common stock at a $0 exercise price. Also on February 28, 729 restricted stock units were converted into common stock. Separately, Beer has an indirect holding of 5,543 Docusign shares held through a trust.
On market performance, shares of Docusign have recovered 9% over the past week and were trading at $46.74 at the time of the report. Despite that short-term gain, the stock is down 38% over the preceding six months.
Product and partnership developments
Docusign has publicized a strategic integration with Anthropic. The collaboration will incorporate Docusign’s Intelligent Agreement Management platform into Anthropic’s Cowork environment, enabling users to manage contracts with natural language prompts. The stated goal of the integration is to streamline contract workflows across multiple corporate functions, including legal, sales, procurement, and human resources.
In addition to the Anthropic partnership, Docusign has introduced new AI-enhanced eSignature features intended to simplify the understanding of contracts and to assist with document preparation. These features are described as targeted responses to obstacles such as complicated legal wording and labor-intensive manual steps.
Analyst stance
Citizens has maintained a Market Outperform rating on Docusign and kept a price target of $124.00. The firm cited Docusign’s market position and noted a $50 billion total addressable market as core factors behind its view. Citizens also highlighted Docusign’s e-signature business, which serves approximately 1.7 million customers, as a notable competitive asset.
Separately, InvestingPro analysis referenced in available data indicates Docusign appears undervalued at current trading levels and assigns the company a financial health score of "GOOD."
What this means
The reported insider sale is a discrete transaction within a broader set of corporate developments that include product innovation and an affirmed positive analyst rating. The company is actively positioning AI capabilities inside its agreement management and eSignature offerings while continuing to balance investor sentiment amid recent share-price volatility.